Compromised LCAT function is associated with increased atherosclerosis

Circulation

Volumn 112, Issue 6, 2005, Pages 879-884

  Hovingh, G Kees ^a   Hutten, Barbara A ^a   Holleboom, Adriaan G ^a   Petersen, Wilma ^a   Rol, Patrick ^a   Stalenhoef, Anton ^b   Zwinderman, Aeilko H ^a   De Groot, Eric ^a   Kastelein, John J P ^a   Kuivenhoven, Jan Albert ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Cardiovascular diseases; Cholesterol; Genetics; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; INTIMA; MALE; PHENOTYPE; PRIORITY JOURNAL; THICKNESS; TRIACYLGLYCEROL BLOOD LEVEL; TUNICA MEDIA;

ADULT; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CHOLESTEROL, HDL; FEMALE; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; REFERENCE VALUES; TUNICA INTIMA; TUNICA MEDIA;

EID: 23844493144     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.540427     Document Type: Article

References (44)

1. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002;161:1-16.
2. Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis. 1999;144:285-301.
3. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
4. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJP. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105:2159-2165.
5. Singaraja RR, Brunham LR, Visscher H, Kastelein JJ, Hayden MR. Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol. 2003;23:1322-1332.
6. Sparrow CP, Baffic J, Lam MH, Lund EG, Adams AD, Fu X, Hayes N, Jones AB, Macnaul KL, Ondeyka J, Singh S, Wang J, Zhou G, Moller DE, Wright SD, Menke JG. A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem. 2002;277:10021-10027.
7. Ikewaki K, Matsunaga A, Han H, Watanabe H, Endo A, Tohyama J, Kuno M, Mogi J, Sugimoto K, Tada N, Sasaki J, Mochizuki S. A novel two nucleotide deletion in the apolipoprotein A-I gene, apoA-1 Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease. Atherosclerosis. 2004;172:39-45.
8. Hovingh GK, Brownlie A, Bisoendial RJ, Dube MP, Levels JHM, Petersen W, Dullaart RPF, Stroes ESG, Zwinderman AH, de Grooth E, Hayden MR, Kuivenhoven JA, Kastelein JJP. A novel ApoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness and premature coronary artery disease. J Am Coll Cardiol. 2004;44:1429-1435.
9. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crow T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
10. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167.
11. Norum KR, Gjone E. Familial serum-cholesterol esterification failure: a new inborn error of metabolism. Biochim Biophys Acta. 1967;144:698-700.
12. Carlson LA, Philipson B. Fish-eye disease: a new familial condition with massive corneal opacities and dyslipoproteinaemia. Lancet. 1979;2:922-924.
13. Pritchard PH, Hill JS. Genetic disorders of lecithin:cholesterol acyltransferase. In: Betteridge DJ, Illingworth DR, Shepherd J, eds. Lipoproteins in Health and Disease. 1st ed. London, UK: Arnold; 1999:799-814.
14. Furbee JW Jr, Parks JS. Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition. Atherosclerosis. 2002;165:89-100.
15. Santamarina-Fojo S, Lambert G, Hoeg JM, Brewer HB Jr. Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol. 2000;11:267-275.
16. Kuivenhoven JA, Wiebusch H, Pritchard PH, Funke H, Benne R, Assmann G, Kastelein JJP. An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease). J Clin Invest. 1996;98:358-364.
17. Funke H, von Eckardstein A, Pritchard PH, Albers JJ, Kastelein JJ, Droste C, Assmann G. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci USA. 1991;88:4855-4859.
18. Kastelein JJ, Pritchard PH, Erkelens DW, Kuivenhoven JA, Albers JJ, Frohlich JJ. Familial high-density-lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of Dutch descent. J Intern Med. 1992;231:413-419.
19. Kuivenhoven JA, van Voorst tot Voorst EJ, Wiebusch H, Marcovina SM, Funke H, Assmann G, Pritchard PH, Kastelein JJP. A unique genetic and biochemical presentation of fish-eye disease. J Clin Invest. 1995;96:2783-2791.
20. Frohlich J, McLeod R, Pritchard PH, Fesmire J, McConathy W. Plasma lipoprotein abnormalities in heterozygotes for familial lecithin:cholesterol acyltransferase deficiency. Metabolism. 1988;37:3-8.
21. Kuivenhoven JA, Stalenhoef AF, Hill JS, Demacker PN, Errami A, Kastelein JJ, Pritchard PH. Two novel molecular defects in the LCAT gene are associated with fish eye disease. Arterioscler Thromb Vasc Biol. 1996;16:294-303.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
23. Pruvot I, Fievet C, Durieux C, Vu DN, Fruchart JC. Electroimmuno- and immunonephelometric assays of apolipoprotein A-I by using a mixture of monoclonal antibodies. Clin Chem. 1988:34:2048-2052.
24. Heuck CC, Schlierf G. Nephelometry of apolipoprotein B in human serum. Clin Chem. 1979;25:221-226.
25. de Groot E, Jukema IW, Montauban van Swijndregt AD, Zwinderman AH, Ackerstaff RG, van der Steen AF, Bom N, Lie KI, Bruschke AV. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statirc Study (REGRESS). J Am Coll Cardiol. 1998;31:1561-1567.
26. Peelman F, Vandekerckhove I, Rosseneu M. Structure and function of lecithin cholesterol acyl transferase: new insights from structural predictions and animal models. Curr Opin Lipidol. 2000;11:155-160.
27. Miettinen HE, Gylling H, Tenhunen I, Virtamo J, Jauhiainen M, Huttunen JK, Kantola I, Miettinen TA, Kontula K. Molecular genetic study of Finns with hypoalphalipoproteinemia and hyperalphalipoproteinemia: a novel Gly230 Arg mutation (LCAT[Fin]) of lecithin:cholesterol acyltransferase (LCAT) accounts for 5% of cases with very low serum HDL cholesterol levels. Arterioscler Thromb Vasc Biol. 1998;18:591-598.
28. Wang CS, Alaupovic P, Gregg RE, Brewer HB Jr. Studies on the mechanism of hypertriglyceridemia in Tangier disease: determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes. Biochim Biophys Acta. 1987;920:9-19.
29. Ng DS, Leiter LA, Vezina C, Connelly PW, Hegele RA. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest. 1994;93:223-229.
30. Ng DS, Xie C, Maguire GF, Zhu X, Ugwu F, Lam E, Connelly PW. Hypertriglyceridemia in lecithin-cholesterol acyltransferase-deficient mice is associated with hepatic overproduction of triglycerides, increased lipogenesis, and improved glucose tolerance. J Biol Chem. 2004;279:7636-7642.
31. Solajic-Bozicevic N, Stavljenic A, Sesto M. Lecithin:cholesterol acyltransferase activity in patients with acute myocardial infarction and coronary heart disease. Artery. 1991;18:326-340.
32. Wells IC, Peitzmeier G, Vincent JK. Lecithimcholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol. 1986;45:303-310.
33. Rader DJ, Ikewaki K, Duverger N, Schmidt H, Pritchard H, Frohlich J, Clerc M, Dumon MF, Fairwell T, Zech L. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest. 1994;93:321-330.
34. van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, Brooks-Wilson A, Zwinderman AH, Smit AJ, Smelt AH, Groen AK, Hayden MR, Kastelein JJP. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet. 2002;359:37-42.
35. Hovingh GK, de Groot E, van der Steeg WA, Boekholdt SM. Hutten BA, Kuivenhoven JA, Kastelein JJP. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol. 2005;16:139-145.
36. Ayyobi AF, McGladdery SH, Chan S, Mancin J, Hil JS, Frohlich JJ. Lecithin:cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis. 2004;177:361-366.
37. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PH, Andresen I, Hayden MR, Kastelein JJ, Stroes ESG. Restoration of endotheiial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944-2948.
38. Vohl MC, Neville TA, Kumarathasan R, Braschi S, Sparks DL. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochemistry. 1999;38:5976-5981.
39. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
40. Pirro M, Siepi D, Lupattelli G, Roscini AR, Schillaci G, Gemelli F. Vaudo G, Marchesi S, Pasqualini L, Mannorino E. Plasma C-reactive protein in subjects with hypo/hyperalphalipoproteinemias. Metabolism. 2003;52:432-436.
41. Rader DJ, Maugeais C. Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention. Mol Med Today. 2000;6:170-175.
42. Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, Verreth W, Stengel D, Ninoi E, Navab M, Mackness B, Mackness M, Holvoet P. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation. 2003;107:1640-1646.
43. Zhang A-H, Gao S, Fan J, Huang W, Zhao T-Q, Liu G. Increased plasma HDL cholesterol levels and biliary cholesterol excretion in hamster by LCAT overexpression. FEBS Lett. 2004;570:25-29.
44. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA, Barter PJ. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005;111:1543-1550.